Department of Microbiology, University of Delhi South Campus, New Delhi, 110021, India.
Appl Biochem Biotechnol. 2013 Apr;169(8):2290-302. doi: 10.1007/s12010-013-0150-1. Epub 2013 Feb 27.
Shikimic acid has wide use in pharmaceuticals due to its application in the synthesis of drug Tamiflu used in the treatment of Swine flu. The high cost and limited availability of shikimic acid isolated from plants has impeded the use of this valuable building block of the drug. In this context, fermentation route to produce shikimic acid from renewable resources has become increasingly attractive. The present study was embarked upon isolation of wild-type microorganisms able to produce shikimic acid. Out of the 42 isolates obtained from the soil, isolate GR-21 was selected as the best with initial production of 0.54 g/L shikimic acid and later identified as Citrobacter sp. The process optimization resulted in 14-fold increase in the shikimic acid production, thereby claiming this process to be a sustainable alternative for the production of this important biomolecule. The process was further scaled up to 14 L bioreactor to validate the production of shikimic acid. Further, the product formed is shikimic acid was confirmed by FTIR analysis. The current studies suggest that the selected isolate could be used as a promising agent to fulfill the worldwide demand of shikimic acid.
莽草酸因其在治疗猪流感的药物达菲（Tamiflu）合成中的应用，在药物领域有着广泛的用途。从植物中分离得到的莽草酸成本高且供应有限，这阻碍了这种药物宝贵结构单元的应用。在这种情况下，利用可再生资源通过发酵途径生产莽草酸变得越来越有吸引力。本研究着手从土壤中分离能够生产莽草酸的野生型微生物。从获得的 42 个分离物中，选择分离物 GR-21 作为最佳分离物，其初始莽草酸产量为 0.54 g/L，后来被鉴定为柠檬酸杆菌属（Citrobacter sp.）。通过工艺优化，莽草酸的产量增加了 14 倍，从而声称该工艺是生产这种重要生物分子的可持续替代方法。该工艺进一步放大到 14 L 生物反应器，以验证莽草酸的生产。此外，通过傅里叶变换红外（FTIR）分析确认形成的产物为莽草酸。目前的研究表明，所选分离物可用作有前途的试剂，以满足全球对莽草酸的需求。
